MED23 and lung cancer: To investigate the role of Med23 in lung cancer, we constructed a conditional Med23-knockout mouse model (Med23f/f), in which Med23 deletion in a small percentage of pulmonary cells was achieved by intranasal delivery of adenoviral Cre recombinase (Adeno Cre) when the mice were 6–8 weeks old.